Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn Sells 2,311 Shares

Twist Bioscience Co. (NASDAQ:TWST) COO Patrick John Finn sold 2,311 shares of the stock in a transaction that occurred on Friday, May 3rd. The stock was sold at an average price of $37.13, for a total value of $85,807.43. Following the sale, the chief operating officer now directly owns 173,895 shares of the company’s stock, valued at $6,456,721.35. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Patrick John Finn also recently made the following trade(s):

• On Tuesday, April 23rd, Patrick John Finn sold 2,174 shares of Twist Bioscience stock. The shares were sold at an average price of $30.12, for a total transaction of $65,480.88.
• On Tuesday, April 2nd, Patrick John Finn sold 492 shares of Twist Bioscience stock. The stock was sold at an average price of $32.74, for a total transaction of $16,108.08.

Twist Bioscience Stock Down 3.4 %

Shares of NASDAQ:TWST traded down $1.54 during midday trading on Tuesday, hitting $43.13. The stock had a trading volume of 1,808,210 shares, compared to its average volume of 997,886. The business’s 50-day simple moving average is $34.11 and its 200-day simple moving average is $31.34. Twist Bioscience Co. has a 12 month low of $11.81 and a 12 month high of $44.92. The company has a market cap of $2.51 billion, a P/E ratio of -12.84 and a beta of 1.64.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($0.84) by $0.05. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The company had revenue of $75.30 million for the quarter, compared to analyst estimates of $70.70 million. During the same period in the previous year, the business earned ($1.06) EPS. Twist Bioscience’s revenue for the quarter was up 25.1% compared to the same quarter last year. As a group, equities analysts predict that Twist Bioscience Co. will post -3.17 earnings per share for the current year.

Institutional Trading of Twist Bioscience

A number of hedge funds have recently made changes to their positions in the business. ARK Investment Management LLC raised its stake in Twist Bioscience by 6.3% in the 4th quarter. ARK Investment Management LLC now owns 7,213,257 shares of the company’s stock valued at $265,881,000 after acquiring an additional 427,274 shares during the period. Artisan Partners Limited Partnership grew its stake in shares of Twist Bioscience by 111.3% in the fourth quarter. Artisan Partners Limited Partnership now owns 3,723,305 shares of the company’s stock worth $137,241,000 after purchasing an additional 1,961,621 shares during the last quarter. Sumitomo Mitsui Trust Holdings Inc. increased its holdings in Twist Bioscience by 2.9% in the fourth quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock valued at $132,086,000 after purchasing an additional 99,511 shares during the period. Nikko Asset Management Americas Inc. raised its position in Twist Bioscience by 2.9% during the 4th quarter. Nikko Asset Management Americas Inc. now owns 3,583,443 shares of the company’s stock worth $131,835,000 after purchasing an additional 99,511 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in Twist Bioscience by 29.0% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,267,708 shares of the company’s stock worth $46,732,000 after buying an additional 284,884 shares during the period.

Analyst Ratings Changes

Several analysts have issued reports on the company. Evercore ISI lifted their price target on Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research note on Friday. The Goldman Sachs Group raised Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their target price for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Scotiabank raised their price target on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research note on Monday. Robert W. Baird boosted their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday. Finally, Barclays raised their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an “overweight” rating in a research report on Friday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $42.50.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.